William Salibe-Filho

William Salibe-Filho

Auto-generated profile, based on publicly available information

William Salibe-Filho

Universidade de São Paulo

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
WSWilliam Salibe-Filho
William Salibe-Filho
TAThaís L. S. Araujo
Thaís L. S. Araujo
EMEverton G. Melo
Everton G. Melo
LCLuiza B. C. T. Coimbra
Luiza B. C. T. Coimbra
MLMonica S. Lapa
Monica S. Lapa
MTMario Terra-Filho
Mario Terra-Filho
The pathophysiological mechanisms underlying chronic thromboembolic pulmonary hypertension (CTEPH) are still unclear. Endothelial cell (EC) remodeling is believed to contribute to this pulmonary disease triggered by thrombus and hemodynamic forces disbalance. Recently, we showed that HSP70 levels decrease by proatherogenic shear stress. Molecular chaperones play a major role in proteostasis in neurological, cancer and inflammatory/ infectious diseases. To shed light on microvascular responses in CTEPH, we characterized the expression of molecular chaperones and annexin A2, a component of the fibrinolytic system. There is no animal model that reproduces microvascular changes in CTEPH, and this fact led us to isolated endothelial cells from patients with CTEPH undergoing pulmonary endarterectomy (PEA). We exposed CTEPH-EC and control human pulmonary endothelial cells (HPAEC) to high- (15 dynes/cm2) or low- (5 dynes/cm2) shear stress. After high-magnitude shear stress HPAEC upregulated heat shock protein 70kDa (HSP70) and the HSP ER paralogs 78 and 94kDa glucose-regulated protein (GRP78 and 94), whereas CTEPH-ECs failed to exhibit this response. At static conditions, both HSP70 and HSP90 families in CTEPH-EC are decreased. Importantly, immunohistochemistry analysis showed that HSP70 expression was downregulated in vivo, and annexin A2 was upregulated. Interestingly, wound healing and angiogenesis assays revealed that HSP70 inhibition with VER-155008 further impaired CTEPH-EC migratory responses. These results implicate HSP70 as a novel master regulator of endothelial dysfunction in type 4 PH. Overall, we first show that global failure of HSP upregulation is a hallmark of CTEPH pathogenesis and propose HSP70 as a potential biomarker of this condition.

12 April 2023 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
WSWilliam Salibe-Filho1
William Salibe-Filho1
FOFrancini Rossetto de Oliveira1
Francini Rossetto de Oliveira1
MTMario Terra-Filho1
Mario Terra-Filho1
This review aimed to provide an overview of pulmonary arteriovenous malformations, including the major clinical and radiological presentations, investigation, and treatment algorithm of the condition. The primary etiology of pulmonary arteriovenous malformations is hereditary hemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber syndrome, with mutations in the ENG gene on chromosome 9 (HHT type 1) or in the ACVRL1/ALK1 complex (HHT type 2). Epistaxis should always be evaluated when repeated, when associated with anemia, and in some cases of hypoxemia. In the investigation, contrast echocardiography and chest CT are essential for evaluating this condition. Embolization is the best treatment choice, especially for correction in cases of hypoxemia or to avoid systemic infections. Finally, disease management was addressed in special conditions such as pregnancy. CT follow-up should be performed every 3-5 years, depending on the size of the afferent and efferent vessels, and antibiotic prophylactic care should always be oriented. Ultimately, knowledge of the disease by health professionals is a crucial point for the early diagnosis of these patients in clinical practice, which can potentially modify the natural course of the disease.

1 January 2019 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
PDF file
WSWilliam Salibe-Filho
William Salibe-Filho
BPBruna Mamprim Piloto
Bruna Mamprim Piloto
EOEllen Pierre de Oliveira
Ellen Pierre de Oliveira
MCMarcela Araújo Castro
Marcela Araújo Castro
BABreno Boueri Affonso
Breno Boueri Affonso
MTMário Terra-Filho
Mário Terra-Filho
Objective: To present a case series of pulmonary arteriovenous malformations (PAVMs), describing the main clinical findings, the number/location of pulmonary vascular abnormalities, the clinical complications, and the treatment administered. Methods: This was a retrospective observational study evaluating patients with PAVM divided into two groups: hereditary hemorrhagic telangiectasia (HHT); and idiopathic PAVM (iPAVM). Results: A total of 41 patients were selected for inclusion, but only 33 had PAVMs. After clinical evaluation, 27 and 6 were diagnosed with HHT and iPAVM, respectively. In the HHT group, the mean age was 49.6 years and 88.9% were female. In that group, 4 patients had an SpO2 of < 90% and the most common clinical finding was epistaxis. In the iPAVM group, the mean age was 48.1 years and 83.3% were female. In that group, 3 patients had an SpO2 of < 90%. Computed tomographic pulmonary angiography showed that most of the PAVMs were in the lower lobes: 56.4% in the HHT group and 85.7% in the iPAVM group. Embolization was performed in 23 patients (in both groups). At this writing, 10 patients are scheduled to undergo the procedure. One of the patients who underwent embolization was subsequently referred for pulmonary resection. Conclusions: In both of the PAVM groups, there was a predominance of women and of fistulas located in the lower lobes. Few of the patients had respiratory symptoms, and most had an SpO2 > 90%. The treatment chosen for all patients was percutaneous transcatheter embolization.

1 January 2020 in Clinics
Verified
Journal Article
Open access
PDF file
CFCaio Julio Cesar dos Santos Fernandes
Caio Julio Cesar dos Santos Fernandes
EOEllen Pierre de Oliveira
Ellen Pierre de Oliveira
WSWillian Salibe-Filho
Willian Salibe-Filho
MTMario Terra-Filho
Mario Terra-Filho
CJCarlos Vianna Poyares Jardim
Carlos Vianna Poyares Jardim
RSRogerio de Souza
Rogerio de Souza
Chronic thromboembolic pulmonary hypertension (CTEPH) is a unique form of pulmonary hypertension (PH) that arises from obstruction of the pulmonary vessels by recanalized thromboembolic material. CTEPH has a wide range of radiologic presentations. Commonly, it presents as main pulmonary artery enlargement, peripheral vascular obstructions, bronchial artery dilations, and mosaic attenuation patterns. Nevertheless, other uncommon presentations have been described, such as lung cavities. These lesions may be solely related to chronic lung parenchyma ischemia but may also be a consequence of concomitant chronic infectious conditions. The objective of this study was to evaluate the different etiologies that cause lung cavities in CTEPH patients. A retrospective data analysis of the medical records of CTEPH patients in a single reference PH center that contained or mentioned lung cavities was conducted between 2013 and 2016. Seven CTEPH patients with lung cavities were identified. The cavities had different sizes, locations, and wall thicknesses. In two patients, the cavities were attributed to pulmonary infarction; in 5 patients, an infectious etiology was identified. Despite the possibility of being solely associated with chronic lung parenchyma ischemia, most cases of lung cavities in CTEPH patients were associated with chronic granulomatous diseases, reinforcing the need for active investigation of infectious agents in this setting.

14 April 2025 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
VAVeronica Moreira Amado1
Veronica Moreira Amado1
CFCaio Júlio César dos Santos Fernandes2
Caio Júlio César dos Santos Fernandes2
WSWilliam Salibe-Filho2
William Salibe-Filho2
MGMarcelo Basso Gazzana3
Marcelo Basso Gazzana3
ARAna Thereza Rocha4
Ana Thereza Rocha4
SMSuzana Minamoto
Suzana Minamoto
Venous thromboembolism (VTE) is the third most common acute cardiovascular syndrome after acute myocardial infarction and stroke. In recent years, there has been an increase in the incidence of VTE, related to population aging and common comorbidities in the elderly, including chronic cardiorespiratory disease and cancer. On the other hand, disease-related mortality, particularly for pulmonary embolism (PE), shows a decreasing trend, which can be explained by improvements in diagnostic imaging, advances in available therapies, and greater adherence to patient management protocols. The guidelines presented here provide recommendations for the pharmacological treatment of PE in Brazil, on the basis of scientific evidence and with a focus on common practical issues. Six Patient, Intervention, Comparison, and Outcome questions were developed by a group of experts on the topic. Systematic reviews of randomized clinical trials were conducted for each question, with meta-analyses being performed when possible. The level of evidence and strength of recommendation were defined in accordance with the Grading of Recommendations Assessment, Development, and Evaluation approach. With these guidelines, we expect to provide relevant, up-to-date information on the pharmacological treatment of PE.

11 September 2025 in Clinics
Verified
Journal Article
Open access
CFCaio Julio Cesar dos Santos Fernandes
Caio Julio Cesar dos Santos Fernandes
WSWilliam Salibe-Filho
William Salibe-Filho
JAJosé Leônidas Alves-Jr
José Leônidas Alves-Jr
CJCarlos Vianna Poyares Jardim
Carlos Vianna Poyares Jardim
TVTúlio Martins Vieira
Túlio Martins Vieira
RSRogerio de Souza
Rogerio de Souza
To evaluate the effects of Riociguat treatment in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) at a Brazilian reference center. This observational study was conducted at INCOR-SP and included 8 patients diagnosed with CTEPH between 2016 and 2024 who were treated with Riociguat. Clinical parameters (NYHA functional class, BNP levels, and 6-minute walk distance) and hemodynamic measurements (right atrial pressure, cardiac index, and pulmonary vascular resistance) were assessed pre- and post-treatment, along with risk stratification using COMPERA 2.0. The retrospective cohort (mean age 56 ± 17 years; 100 % female) comprised 2 inoperable patients and 6 with residual PH post-PEA. Significant improvements were observed in functional class (p < 0.05), 6-minute walk distance (increased from 398.5 ± 45 m to 413 ± 110 m; p < 0.05), and BNP levels (decreased from 140 ± 191 pg/mL to 28 ± 235 pg/mL; p < 0.05). Additionally, risk stratification according to COMPERA 2.0 improved significantly. However, no significant changes were detected in the hemodynamic parameters (mean pulmonary arterial pressure, right atrial pressure, cardiac index, or pulmonary vascular resistance). Riociguat treatment significantly enhanced functional capacity, reduced BNP levels, and improved risk stratification in CTEPH patients, corroborating international evidence. The absence of significant hemodynamic changes underscores the need for larger, prospective studies to fully elucidate the cardiovascular impact of Riociguat. Importantly, the limited availability of Riociguat in Brazil remains a critical challenge that hinders the effective management of CTEPH.